<DOC>
	<DOCNO>NCT00006890</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth multiple myeloma stop blood flow tumor . Prednisone may effective prevent relapse multiple myeloma . PURPOSE : Randomized phase II trial compare effectiveness two dos thalidomide combine prednisone follow peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Thalidomide Prednisone Following Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose thalidomide ( 200 mg v 400 mg ) combine prednisone optimally tolerate dose use maintenance therapy follow autologous stem cell transplantation patient multiple myeloma . II . Compare response rate patient treat regimen . III . Compare progression-free overall survival patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord age ( 60 vs 60 ) . Within 60-100 day autologous stem cell transplantation , patient randomize 1 2 treatment arm . Arm I : Patients receive low dose oral thalidomide daily oral prednisone every day . Arm II : Patients receive high dose thalidomide daily oral prednisone every day . Treatment continue 2 year absence disease progression unacceptable toxicity . Patients follow monthly 6 month , every 3 month , time disease progression . PROJECTED ACCRUAL : A total 40-80 patient ( 20-40 per arm ) accrue study within 17-21 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven multiple myeloma Initial diagnosis must confirm one follow prior initial treatment multiple myeloma : Biopsy osteolytic lesion soft tissue tumor compose plasma cell Bone marrow aspirate and/or biopsy demonstrate least 10 % plasmacytosis Bone marrow contain less 10 % plasma cell least 1 bony lesion Mprotein criterion outline Measurable serum Mcomponent IgG , IgA , IgD , IgE initial diagnosis OR If light chain disease ( urine Mprotein ) present , urinary excretion light chain ( Bence Jones ) protein must least 1.0 g/24 hour time initial diagnosis Must undergone autologous stem cell transplantation within 1 year begin initial chemotherapy multiple myeloma Must randomize 60100 day autologous stem cell infusion No evidence progressive disease PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : See Disease Characteristics Granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : AST and/or ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN Renal : Creatinine great 3 time ULN Cardiovascular : No uncontrolled hypertension Other : Not pregnant nursing Negative pregnancy test Fertile female patient must use 2 effective method contraception ( 1 barrier 1 hormonal ) 1 month study Fertile male patient must use effective barrier contraception 1 month study No medical condition would preclude long term use prednisone thalidomide No malignancy within past 5 year except adequately treat squamous cell basal cell skin cancer carcinoma situ cervix No diabetes end stage organ damage No history gastric ulceration bleed No avascular necrosis hips No peripheral neuropathy cause symptomatic dysfunction Sensory symptom induce vincristine allow No demonstrated hypersensitivity thalidomide component No major medical illness would increase risk preclude study No employment prohibits use sedative ( due know effect thalidomide ) PRIOR CONCURRENT THERAPY : Biologic : See Disease Characteristics No prior thalidomide Chemotherapy : See Disease Characteristics Endocrine : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent anticancer treatment No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>